These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25700648)

  • 21. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis].
    Ndongo S; Pouye A; Lekpa FK; Bihéhé DM; Tiendrebeogo J; Ndao AC; Ka MM; Moreira Diop T
    Med Sante Trop; 2012; 22(4):385-9. PubMed ID: 23352953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic Therapies for Rheumatologic and Autoimmune Conditions.
    Bays AM; Gardner G
    Med Clin North Am; 2016 Jul; 100(4):719-31. PubMed ID: 27235612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The pulmonological manifestations of rheumatoid arthritis].
    Bernscherer G; Karabélyos C; Tarján Z
    Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].
    Krüger K; Wollenhaupt J; Albrecht K; Alten R; Backhaus M; Baerwald C; Bolten W; Braun J; Burkhardt H; Burmester G; Gaubitz M; Gause A; Gromnica-Ihle E; Kellner H; Kuipers J; Krause A; Lorenz HM; Manger B; Nüßlein H; Pott HG; Rubbert-Roth A; Schneider M; Specker C; Schulze-Koops H; Tony HP; Wassenberg S; Müller-Ladner U;
    Z Rheumatol; 2012 Sep; 71(7):592-603. PubMed ID: 22930110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How do the biologics fit into the current DMARD armamentarium?
    Kalden JR
    J Rheumatol Suppl; 2001 Jun; 62():27-35. PubMed ID: 11409155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up.
    Tiippana-Kinnunen T; Paimela L; Kautiainen H; Laasonen L; Leirisalo-Repo M
    Scand J Rheumatol; 2010; 39(1):12-8. PubMed ID: 20132065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What is the future of targeted therapy in rheumatology: biologics or small molecules?
    Mócsai A; Kovács L; Gergely P
    BMC Med; 2014 Mar; 12():43. PubMed ID: 24620738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TNF inhibitors for inflammatory arthritis in New Zealand.
    Grainger R; Harrison A
    N Z Med J; 2005 Oct; 118(1224):U1706. PubMed ID: 16258581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
    Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
    Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction].
    Yamaguchi Y; Yamamoto K
    Clin Calcium; 2007 Apr; 17(4):463-73. PubMed ID: 17404474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis.
    Tvete IF; Natvig B; Gåsemyr J; Meland N; Røine M; Klemp M
    PLoS One; 2015; 10(9):e0137258. PubMed ID: 26356639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.
    Bykerk VP; Östör AJ; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Aassi M; Sibilia J
    Clin Rheumatol; 2015 Mar; 34(3):563-71. PubMed ID: 25604316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
    Braun J; Kay J
    Expert Opin Drug Saf; 2017 Mar; 16(3):289-302. PubMed ID: 28068848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
    Osiri M; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.